APO Research
Talk to an analyst

APO RESEARCH · REPORT

Aneurysmal Subarachnoid Hemorrhage Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Outlook and Growth Opportunities 2026

19 December 2025193 pages

Choose your research edition.

Industry ResearchAneurysmal Subarachnoid Hemorrhage Drugs Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Aneurysmal Subarachnoid Hemorrhage Drugs Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Aneurysmal Subarachnoid Hemorrhage Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Aneurysmal Subarachnoid Hemorrhage Drugs Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Aneurysmal Subarachnoid Hemorrhage Drugs Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global Aneurysmal Subarachnoid Hemorrhage Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Aneurysmal Subarachnoid Hemorrhage Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Aneurysmal Subarachnoid Hemorrhage Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Aneurysmal Subarachnoid Hemorrhage Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Aneurysmal Subarachnoid Hemorrhage Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Aneurysmal Subarachnoid Hemorrhage Drugs market include Arbor Pharmaceuticals, Orexo AB, PDS Biotechnology Corporation, Pharmaxis, Purdue Pharma, Pfizer, Mylan N.V, Johnson and Johnson and Sun Pharmaceutical Industries, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Aneurysmal Subarachnoid Hemorrhage Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Aneurysmal Subarachnoid Hemorrhage Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Aneurysmal Subarachnoid Hemorrhage Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Aneurysmal Subarachnoid Hemorrhage Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Aneurysmal Subarachnoid Hemorrhage Drugs Segment by Company

Arbor Pharmaceuticals

Orexo AB

PDS Biotechnology Corporation

Pharmaxis

Purdue Pharma

Pfizer

Mylan N.V

Johnson and Johnson

Sun Pharmaceutical Industries

Teva Pharmaceutical

Aneurysmal Subarachnoid Hemorrhage Drugs Segment by Type

Osmotic Agent

Anticonvulsant

Calcium Channel Blocker

Stool Softener

Opioid Analgesic

Other Drugs

Aneurysmal Subarachnoid Hemorrhage Drugs Segment by Application

Hospital

Clinic

Others

Aneurysmal Subarachnoid Hemorrhage Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Aneurysmal Subarachnoid Hemorrhage Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Aneurysmal Subarachnoid Hemorrhage Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Aneurysmal Subarachnoid Hemorrhage Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Aneurysmal Subarachnoid Hemorrhage Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aneurysmal Subarachnoid Hemorrhage Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Aneurysmal Subarachnoid Hemorrhage Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Aneurysmal Subarachnoid Hemorrhage Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Aneurysmal Subarachnoid Hemorrhage Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Aneurysmal Subarachnoid Hemorrhage Drugs industry.

Chapter 3: Detailed analysis of Aneurysmal Subarachnoid Hemorrhage Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Aneurysmal Subarachnoid Hemorrhage Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Aneurysmal Subarachnoid Hemorrhage Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Aneurysmal Subarachnoid Hemorrhage Drugs Industry Trends Table 2. Aneurysmal Subarachnoid Hemorrhage Drugs Industry Drivers Table 3. Aneurysmal Subarachnoid Hemorrhage Drugs Industry Opportunities and Challenges Table 4. Aneurysmal Subarachnoid Hemorrhage Drugs Industry Restraints Table 5. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue Share by Company (2021-2026) Table 7. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Aneurysmal Subarachnoid Hemorrhage Drugs Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Aneurysmal Subarachnoid Hemorrhage Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Aneurysmal Subarachnoid Hemorrhage Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Aneurysmal Subarachnoid Hemorrhage Drugs Company, Product Type & Application Table 13. Global Aneurysmal Subarachnoid Hemorrhage Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Aneurysmal Subarachnoid Hemorrhage Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Osmotic Agent Table 18. Significant Companies of Anticonvulsant Table 19. Significant Companies of Calcium Channel Blocker Table 20. Significant Companies of Stool Softener Table 21. Significant Companies of Opioid Analgesic Table 22. Significant Companies of Other Drugs Table 23. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 24. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Type (2021-2026) & (Tons) Table 25. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Type (2027-2032) & (Tons) Table 26. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume Share by Type (2021-2026) Table 27. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume Share by Type (2027-2032) Table 28. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 30. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 31. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type (2021-2026) Table 32. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type (2027-2032) Table 33. Significant Companies of Hospital Table 34. Significant Companies of Clinic Table 35. Significant Companies of Others Table 36. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 37. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Application (2021-2026) & (Tons) Table 38. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Application (2027-2032) & (Tons) Table 39. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume Share by Application (2021-2026) Table 40. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume Share by Application (2027-2032) Table 41. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 43. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 44. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application (2021-2026) Table 45. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application (2027-2032) Table 46. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 47. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region (2021-2026) & (Tons) Table 48. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Region (2021-2026) Table 49. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region (2027-2032) & (Tons) Table 50. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Region (2027-2032) Table 51. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 52. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 53. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Region (2021-2026) Table 54. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 55. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Region (2027-2032) Table 56. Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Average Price (US$/Ton) by Region (2021-2026) Table 57. Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Average Price (US$/Ton) by Region (2027-2032) Table 58. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 59. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2026) & (Tons) Table 61. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Country (2021-2026) Table 62. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2027-2032) & (Tons) Table 63. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Country (2027-2032) Table 64. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 65. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Market Share by Country (2021-2026) Table 66. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 67. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Market Share by Country (2027-2032) Table 68. Arbor Pharmaceuticals Company Information Table 69. Arbor Pharmaceuticals Business Overview Table 70. Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 71. Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 72. Arbor Pharmaceuticals Recent Development Table 73. Orexo AB Company Information Table 74. Orexo AB Business Overview Table 75. Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 76. Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 77. Orexo AB Recent Development Table 78. PDS Biotechnology Corporation Company Information Table 79. PDS Biotechnology Corporation Business Overview Table 80. PDS Biotechnology Corporation Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 81. PDS Biotechnology Corporation Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 82. PDS Biotechnology Corporation Recent Development Table 83. Pharmaxis Company Information Table 84. Pharmaxis Business Overview Table 85. Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 86. Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 87. Pharmaxis Recent Development Table 88. Purdue Pharma Company Information Table 89. Purdue Pharma Business Overview Table 90. Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 91. Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 92. Purdue Pharma Recent Development Table 93. Pfizer Company Information Table 94. Pfizer Business Overview Table 95. Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 96. Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 97. Pfizer Recent Development Table 98. Mylan N.V Company Information Table 99. Mylan N.V Business Overview Table 100. Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 101. Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 102. Mylan N.V Recent Development Table 103. Johnson and Johnson Company Information Table 104. Johnson and Johnson Business Overview Table 105. Johnson and Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 106. Johnson and Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 107. Johnson and Johnson Recent Development Table 108. Sun Pharmaceutical Industries Company Information Table 109. Sun Pharmaceutical Industries Business Overview Table 110. Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 111. Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 112. Sun Pharmaceutical Industries Recent Development Table 113. Teva Pharmaceutical Company Information Table 114. Teva Pharmaceutical Business Overview Table 115. Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 116. Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio Table 117. Teva Pharmaceutical Recent Development Table 118. Key Raw Materials Table 119. Raw Materials Key Suppliers Table 120. Aneurysmal Subarachnoid Hemorrhage Drugs Distributors List Table 121. Aneurysmal Subarachnoid Hemorrhage Drugs Customers List Table 122. Research Programs/Design for This Report Table 123. Authors List of This Report Table 124. Secondary Sources Table 125. Primary Sources List of Figures Figure 1. Aneurysmal Subarachnoid Hemorrhage Drugs Product Image Figure 2. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales (2021-2032) & (Tons) Figure 5. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Aneurysmal Subarachnoid Hemorrhage Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Osmotic Agent Image Figure 10. Anticonvulsant Image Figure 11. Calcium Channel Blocker Image Figure 12. Stool Softener Image Figure 13. Opioid Analgesic Image Figure 14. Other Drugs Image Figure 15. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 16. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 17. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume Share by Type (2021-2032) Figure 18. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type (2021-2032) Figure 21. Hospital Image Figure 22. Clinic Image Figure 23. Others Image Figure 24. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 25. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 26. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume Share by Application (2021-2032) Figure 27. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 29. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application (2021-2032) Figure 30. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 31. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 32. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 33. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 34. North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. South America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value (2021-2032) & (US$ Million) Figure 41. South America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 42. Middle East & Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value (2021-2032) & (US$ Million) Figure 43. Middle East & Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 44. USA Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. USA Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. USA Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Canada Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Canada Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Canada Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Germany Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Germany Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Germany Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. France Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. France Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. France Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. U.K. Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. U.K. Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. U.K. Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Italy Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Italy Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Italy Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Spain Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Spain Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Spain Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Russia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Russia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Russia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Netherlands Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Netherlands Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Netherlands Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Nordic Countries Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Nordic Countries Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Nordic Countries Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. China Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. China Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. China Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Japan Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Japan Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Japan Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. South Korea Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. South Korea Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. South Korea Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. India Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. India Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. India Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Australia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Australia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Australia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Southeast Asia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Southeast Asia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Southeast Asia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Chile Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Chile Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Chile Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Colombia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Colombia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Colombia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Peru Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Peru Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Peru Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Israel Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Israel Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Israel Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. UAE Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. UAE Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. UAE Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Iran Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Iran Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Iran Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Egypt Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 126. Egypt Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 127. Egypt Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 128. Aneurysmal Subarachnoid Hemorrhage Drugs Value Chain Figure 129. Manufacturing Cost Structure Figure 130. Aneurysmal Subarachnoid Hemorrhage Drugs Sales Mode & Process Figure 131. Direct Comparison with Distribution Share Figure 132. Distributors Profiles Figure 133. Years Considered Figure 134. Research Process Figure 135. Key Executives Interviewed

Scope & coverage.

Types
  • Osmotic Agent
  • Anticonvulsant
  • Calcium Channel Blocker
  • Stool Softener
  • Opioid Analgesic
  • Other Drugs
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Arbor Pharmaceuticals
  • Orexo AB
  • PDS Biotechnology Corporation
  • Pharmaxis
  • Purdue Pharma
  • Pfizer
  • Mylan N.V
  • Johnson and Johnson
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Aneurysmal Subarachnoid Hemorrhage Drugs Market Dynamics
  1. 2.1 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Trends
  2. 2.2 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Drivers
  3. 2.3 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Opportunities and Challenges
  4. 2.4 Aneurysmal Subarachnoid Hemorrhage Drugs Industry Restraints
3 Aneurysmal Subarachnoid Hemorrhage Drugs Market by Company
  1. 3.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Aneurysmal Subarachnoid Hemorrhage Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Aneurysmal Subarachnoid Hemorrhage Drugs Company Ranking (2024-2026)
  6. 3.6 Global Aneurysmal Subarachnoid Hemorrhage Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Aneurysmal Subarachnoid Hemorrhage Drugs Company Product Type and Application
  8. 3.8 Global Aneurysmal Subarachnoid Hemorrhage Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Aneurysmal Subarachnoid Hemorrhage Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Aneurysmal Subarachnoid Hemorrhage Drugs Market by Type
  1. 4.1 Aneurysmal Subarachnoid Hemorrhage Drugs Type Introduction
  2. 4.1.1 Osmotic Agent
  3. 4.1.2 Anticonvulsant
  4. 4.1.3 Calcium Channel Blocker
  5. 4.1.4 Stool Softener
  6. 4.1.5 Opioid Analgesic
  7. 4.1.6 Other Drugs
  8. 4.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Type
  9. 4.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Type (2021-2032)
  11. 4.2.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume Share by Type (2021-2032)
  12. 4.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Type
  13. 4.3.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  14. 4.3.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Type (2021-2032)
  15. 4.3.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type (2021-2032)
5 Aneurysmal Subarachnoid Hemorrhage Drugs Market by Application
  1. 5.1 Aneurysmal Subarachnoid Hemorrhage Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Application
  6. 5.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Application
  10. 5.3.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application (2021-2032)
6 Aneurysmal Subarachnoid Hemorrhage Drugs Regional Sales and Value Analysis
  1. 6.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Region (2027-2032)
  5. 6.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Country, 2025 VS 2032
7 Aneurysmal Subarachnoid Hemorrhage Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales by Country (2027-2032)
  6. 7.4 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Aneurysmal Subarachnoid Hemorrhage Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Arbor Pharmaceuticals
  2. 8.1.1 Arbor Pharmaceuticals Company Information
  3. 8.1.2 Arbor Pharmaceuticals Business Overview
  4. 8.1.3 Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Arbor Pharmaceuticals Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  6. 8.1.5 Arbor Pharmaceuticals Recent Developments
  7. 8.2 Orexo AB
  8. 8.2.1 Orexo AB Company Information
  9. 8.2.2 Orexo AB Business Overview
  10. 8.2.3 Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Orexo AB Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  12. 8.2.5 Orexo AB Recent Developments
  13. 8.3 PDS Biotechnology Corporation
  14. 8.3.1 PDS Biotechnology Corporation Company Information
  15. 8.3.2 PDS Biotechnology Corporation Business Overview
  16. 8.3.3 PDS Biotechnology Corporation Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 PDS Biotechnology Corporation Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  18. 8.3.5 PDS Biotechnology Corporation Recent Developments
  19. 8.4 Pharmaxis
  20. 8.4.1 Pharmaxis Company Information
  21. 8.4.2 Pharmaxis Business Overview
  22. 8.4.3 Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Pharmaxis Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  24. 8.4.5 Pharmaxis Recent Developments
  25. 8.5 Purdue Pharma
  26. 8.5.1 Purdue Pharma Company Information
  27. 8.5.2 Purdue Pharma Business Overview
  28. 8.5.3 Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Purdue Pharma Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  30. 8.5.5 Purdue Pharma Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 Mylan N.V
  38. 8.7.1 Mylan N.V Company Information
  39. 8.7.2 Mylan N.V Business Overview
  40. 8.7.3 Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Mylan N.V Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  42. 8.7.5 Mylan N.V Recent Developments
  43. 8.8 Johnson and Johnson
  44. 8.8.1 Johnson and Johnson Company Information
  45. 8.8.2 Johnson and Johnson Business Overview
  46. 8.8.3 Johnson and Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Johnson and Johnson Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  48. 8.8.5 Johnson and Johnson Recent Developments
  49. 8.9 Sun Pharmaceutical Industries
  50. 8.9.1 Sun Pharmaceutical Industries Company Information
  51. 8.9.2 Sun Pharmaceutical Industries Business Overview
  52. 8.9.3 Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Sun Pharmaceutical Industries Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  54. 8.9.5 Sun Pharmaceutical Industries Recent Developments
  55. 8.10 Teva Pharmaceutical
  56. 8.10.1 Teva Pharmaceutical Company Information
  57. 8.10.2 Teva Pharmaceutical Business Overview
  58. 8.10.3 Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Teva Pharmaceutical Aneurysmal Subarachnoid Hemorrhage Drugs Product Portfolio
  60. 8.10.5 Teva Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Aneurysmal Subarachnoid Hemorrhage Drugs Value Chain Analysis
  2. 9.1.1 Aneurysmal Subarachnoid Hemorrhage Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Aneurysmal Subarachnoid Hemorrhage Drugs Sales Mode & Process
  6. 9.2 Aneurysmal Subarachnoid Hemorrhage Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Aneurysmal Subarachnoid Hemorrhage Drugs Distributors
  9. 9.2.3 Aneurysmal Subarachnoid Hemorrhage Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst